Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ANAVEX LIFE SCIENCES CORP. (AVXL)

Anavex names interim CEO Terrie Kellmeyer as permanent CEO and board member

Neutral Impact 4 of 5 leadership Written later

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., who had served as interim CEO since May 4, 2026, as President and Chief Executive Officer effective immediately, and added her to the Board. The Board reduced its size from six to five seats and is searching for an additional independent director. Her base salary remains $500,000 with an anticipated bonus of 30% of base salary, and the Board plans to review her employment agreement; the filing contains no financial results.

Key points

  • Appointed CEO and President effective immediately, with appointment dated November 1, 2026
  • Served as interim CEO since May 4, 2026; previously Senior Vice President, Clinical Development from November 2023 to May 2025
  • Annual base salary remains $500,000; anticipated bonus is 30% of base salary
  • Board reduced from six to five seats; search underway for an independent director to fill the fifth seat

The filing

CompanyANAVEX LIFE SCIENCES CORP. (AVXL)
Form8-K, current report
Filed with the SECNov 3, 2026, 8:08 AM ET
Accession number0001731122-26-001395

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.